HER2 음성 유방암에 대한 신보조화학요법 및 베바시주맙

Minckwitz 등(목,)이 이 질문을 연구했습니다.

www.synapsesocial.com/papers/69dd63ebc5e71f7918100e82 — DOI: https://doi.org/10.1056/nejmoa1111065

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials· 2010 · 159 citations
2. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer· 2007 · 3,048 citations
3. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies· 1983 · 1,725 citations
4. A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment· 2009 · 4 citations
5. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival· 2005 · 997 citations